- POSITIVE
Quarterly Revenue Corona Remedies Sep-2026 Quarterly Revenue is Rs 444 Cr which is growth of 22.1% YoY.
- POSITIVE
Quarterly Net Profit Corona Remedies Sep-2026 Quarterly Net Profit is Rs 60 Cr which is growth of 15.4% YoY.
NSE: CORONA | BSE: 544644
Corona Remedies Live Share Price Today, Share Analysis and Chart
aboutCorona Remedies Ltd. is an Indian pharmaceutical company primarily focused on domestic formulations, with a high concentration in chronic and women's healthcare segments. Founded in 2004, the company has established a market position by outpacing the... Read More
2149.60-67.80(-3.06%)
24,887
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Expensive StarThese stocks are bullish, strong in quality and technicals, but expensive in valuation. Investors need to be cautiousView SimilarEmbed DVM
Please subscribe to view forecaster data
Corona Remedies Stock Price Analysis
Day Price Range-3.1% 1 Day return | 2149.6 (LTP) 2,0902,237.4 LowHigh |
|---|---|
Week Price Range4.8% 1 Week return | 2149.6 (LTP) 2,023.32,249.9 LowHigh |
Month Price Range3.4% 1 Month return | 2149.6 (LTP) 1,941.52,249.9 LowHigh |
52 Week Price Range102.4% 1 Year return | 2149.6 (LTP) 1,336.62,292.4 LowHigh |
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Corona Remedies quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 443.7 | 425.6 | 357.2 | 344.7 | 363.4 | 348.6 | 295.1 | 298.5 | 316.3 | 292.5 | ||
Operating Exp. | 345.2 | 329.3 | 291.1 | 259.3 | 282.7 | 276.8 | 239.5 | 228.3 | 247.1 | 241.7 | |
Operating Profit | 96 | 93.1 | 62 | 83.2 | 78.5 | 69.8 | 54.2 | 69.4 | 66.8 | 49.5 | |
Operating Profit Margin % | 21.75% | 22.05% | 17.56% | 24.29% | 21.73% | 20.14% | 18.46% | 23.32% | 21.29% | 17.01% | |
Depr. | 15.1 | 13.2 | 10.3 | 9.5 | 9.2 | 8.9 | 10 | 9.7 | 9.1 | 8.4 | |
Interest | 2.8 | 2.7 | 1.4 | 1.7 | 1.9 | 2 | 2.2 | 2.4 | 2.9 | 3.1 | |
Profit Before Tax | 80.6 | 80.4 | 54.5 | 55.2 | 69.6 | 60.9 | 43.4 | 58.1 | 57.4 | 39.3 | |
Tax | 20.4 | 20.3 | 9.4 | 13.9 | 17.5 | 14.5 | 12.1 | 13.3 | 14.4 | 9.3 | |
Net Profit | 60.2 | 60.1 | 45.1 | 41.3 | 52.2 | 46.4 | 31.3 | 44.8 | 43 | 30 | |
EPS Adj. latest | 9.8 | 9.8 | 7.4 | 6.7 | 8.5 | 7.6 | 5.1 | 7.3 | 7 | 4.9 | |
Net profit TTM | 206.6 | 198.6 | 184.9 | 171.1 | 174.7 | 165.5 | 149.1 | - | - | - | |
Basic EPS TTM | 33.8 | 32.5 | 30.2 | 28 | 28.6 | 27.1 | 47.6 | - | - | - | |
Earnings Transcripts | |||||||||||
Results PDF | |||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Corona Remedies Technical Analysis
Corona Remedies EMA & SMA
Bullish+6
7 bullish, 1 bearish
Bullish7
Bearish1
| 5 Day | 2150.4 |
|---|---|
| 10 Day | 2115.8 |
| 12 Day | 2107.7 |
| 20 Day | 2093.5 |
| 26 Day | 2090.8 |
|---|---|
| 50 Day | 2080.0 |
| 100 Day | 2012 |
| 200 Day | 1813.5 |
Corona Remedies Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202638.7%
Week47.9%
Month60.9%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Corona Remedies Resistance and Support
2159.00
Pivot
| First Resistance | 2228 |
|---|---|
| Second Resistance | 2306.4 |
| Third Resistance | 2375.4 |
| First Support | 2080.6 |
|---|---|
| Second Support | 2011.6 |
| Third Support | 1933.2 |
| Day RSI | 57.2 |
|---|---|
| Day MACD | 17 |
| Day MFI | 56.9 |
| Day MACD Signal Line | -4.1 |
Corona Remedies Beta
| 1 Month | 0.2 |
|---|---|
| 1 Year | - |
| 3 Month | 0.2 |
|---|---|
| 3 Year | - |
Corona Remedies Price Change Analysis
↑3.4%
Over 1 Month
LowHigh
1941.52249.9
↑2.8%
Over 3 Months
LowHigh
1941.52292.4
↑27.2%
Over 6 Months
LowHigh
1602.82292.4
↑102.4%
Over 1 Year
LowHigh
1336.62292.4
Corona Remedies Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| SEPIA INVESTMENTS LIMITED | Bulk | Sell | 10 Sep 2026 | 2050.32 | 2,485,476 | BSE |
| AMUNDI FUNDS ASIA EQUITY CONCENTRATED | Bulk | Purchase | 10 Sep 2026 | 2050 | 312,000 | BSE |
| SBI MUTUAL FUND | Bulk | Purchase | 10 Sep 2026 | 2050 | 680,000 | BSE |
| SBI MUTUAL FUND | Bulk | Purchase | 10 Sep 2026 | 2050 | 860,000 | BSE |
| ANCHOR PARTNERS | Block | Sell | 17 Jun 2026 | 1730 | 161,861 | NSE |
| SEPIA INVESTMENTS LIMITED | Block | Sell | 17 Jun 2026 | 1730 | 4,328,943 | NSE |
| KOTAK MAHINDRA MUTUAL FUND | Block | Purchase | 17 Jun 2026 | 1730 | 161,861 | NSE |
| INVESCO MUTUAL FUND | Block | Purchase | 17 Jun 2026 | 1730 | 289,017 | NSE |
| INDIA ACORN ICAV - ASHOKA WHITEOAK EMERGING MARKETS EQUITY FUND | Block | Purchase | 17 Jun 2026 | 1730 | 148,686 | NSE |
| HDFC MUTUAL FUND | Block | Purchase | 17 Jun 2026 | 1730 | 2,450,000 | NSE |
Corona Remedies Corporate Actions
Corona Remedies Dividend history and yield
Corona Remedies dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Corona Remedies dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
119 Jun 2026 | 10 | FINAL | 19 Jun 2026 | Equity Share |
Corona Remedies Board Meetings
Corona Remedies past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
130 Oct 2026 | Quarterly Results | - |
231 Jul 2026 | Quarterly Results | - |
311 May 2026 | Audited Results & Final Dividend | - |
402 Feb 2026 | Quarterly Results | - |
502 Jan 2026 | Quarterly Results | Inter-alia, to consider and approve the financial results for the period ended September 30, 2025 |
Corona Remedies Research Reports
Corona Remedies research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 108 Dec 2025 | HDFC Securities | - | - | IPO Note | - | -% | |
| 207 Dec 2025 | Deven Choksey | - | - | IPO Subscribe | - | -% | |
| 307 Dec 2025 | Hem Securities | - | - | IPO Subscribe | - | -% | |
| 404 Dec 2025 | ICICI Direct | - | - | IPO Note | - | -% | |
| 504 Dec 2025 | Ventura | - | - | IPO Subscribe | - | -% |
Corona Remedies Corporate Filings
Corona Remedies BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 31 Oct 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | Intimation for Analyst / Investor Meet | |
| 31 Oct 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Newspaper Publication | Newspaper Publication of Unaudited Financial Results for the second quarter and half year ended on September 30, 2026 | |
| 30 Oct 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Analyst / Investor Presentation | |
| 30 Oct 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | Press Release on Financial Results for second quarter and half year ended on September 30, 2026 | |
| 30 Oct 2026 | Corona Remedies Ltd - 544644 - Unaudited Financial Results Along With The Limited Review Reports For Second Quarter And Half Year Ended September 30, 2026 | Unaudited Financial Results along with the Limited Review Reports for the second quarter and half year ended September 30, 2026 |
Corona Remedies Documents
Corona Remedies Earnings Call
Corona Remedies earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 10 Aug 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 03 Aug 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 03 Aug 2026 | Corona Remedies Results Earnings Call for Q1FY27 | AudioVideo |
| 18 May 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 12 May 2026 | Corona Remedies Results Earnings Call for Q4FY26 & Full Year | AudioVideo |
Corona Remedies Annual Reports
Corona Remedies financials, including annual results, balance sheets, and cash flow statements.
| Date | Report Title | Links |
|---|---|---|
| 2026 | Annual Report Mar-2026 | Link |
Corona Remedies Credit Ratings
Corona Remedies credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
Corona Remedies Investor Presentations
Corona Remedies investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 30 Oct 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 31 Jul 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 11 May 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 02 Feb 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 03 Jan 2026 | Corona Remedies Ltd - 544644 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
Corona Remedies - Company Profile
Corona Remedies Management Structure
Corona Remedies management structure with salaries, total experience, and qualifications.
Corona Remedies Board of Directors
Corona Remedies Board of directors with salaries, total experience, and qualifications.
Website: www.coronaremedies.com
About the company - Business Profile
Corona Remedies Ltd. is an Indian pharmaceutical company primarily focused on domestic formulations, with a high concentration in chronic and women's healthcare segments. Founded in 2004, the company has established a market position by outpacing the Indian Pharmaceutical Market (IPM) growth rate through a mix of organic brand building and strategic acquisitions of brands and portfolios from global pharmaceutical entities.
Key Points
- Key Facts: Founded in 2004, headquartered in Ahmedabad, Gujarat. The company was listed on the NSE and BSE in December 2025.
- Operations and Resources: Operates two primary manufacturing units: an EU-GMP and WHO-GMP approved facility in Gujarat and a WHO-GMP approved facility in Solan, Himachal Pradesh.
- Ownership: The company has historically been promoter-led, with strategic investments such as those from CVC Capital Partners (through its affiliate) in previous years.
- Market Significance: Ranks #6 in Women\'s Healthcare, #5 in Pain Management, and #9 in Urology in the Indian market. It serves 71 brands, including 27 "Engine Brands" that drive core growth.
- Business Model and Core Competencies: The model centers on high-margin chronic therapies, which contribute 70.1% to total revenue as of MAT June 2025. It excels in brand-building within specific therapeutic niches and has a track record of integrating acquired brands from multinational corporations.
- Revenue Breakdown (FY25):
- By Segment: Chronic therapies (71.1%), Acute therapies (28.9%).
- By Therapy: Women's Healthcare (34.9%), Pain Management (27.5%), Cardio-Diabetic (20.0%), Urology (11.2%), and others (6.4%).
- By Geography: West (21.5%), South (20.2%), North (18.0%), East (12.4%), and International/Exports (3.7%).
- Financial Performance (Annual FY25):
- Revenue from Operations: INR 1,196.4 crore (Growth from INR 1,014.5 crore in FY24).
- EBITDA: INR 240.0 crore with a margin of 20.1%.
- Profit After Tax (PAT): INR 149.4 crore.
- Key Products and Advancements:
- Acquired 7 distinct brands from Bayer Zydus Pharma in 2025.
- Key acquired brands include Stelbid and Vitneurin from Glaxo Group.
- Strategic investment in La Chandra Pharmalabs for backward integration into Hormone API manufacturing.
- Strategic Partnerships: Maintains in-licensing arrangements with Ferring Pharmaceuticals (Switzerland) for specific products in Women's Healthcare and Urology.
- Employee Base: The company maintains a therapy-focused sales team to manage its pan-India distribution network.
- Strategic Initiatives: Focus on expanding chronic therapy presence, deepening pan-India penetration, and continuing opportunistic brand acquisitions to sustain a growth rate significantly higher than the general IPM.
References